|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Keeping an eye on the diabetic foot: The connection between diabetic eye disease and wound healing in the lower extremity显示文摘Diabetic eye disease is strongly associated with the development of diabetic foot ulcers(DFUs).DFUs are a common and significant complication of diabetes mellitus(DM)that arise from a combination of micro-and macrovascular compromise.Hyperglycemia and associated metabolic dysfunction in DM lead to impaired wound healing,immune dysregulation,peripheral vascular disease,and diabetic neuropathy that predisposes the lower extremities to repetitive injury and progressive tissue damage that may ultimately necessitate amputation.Diabetic retinopathy(DR)is caused by cumulative damage to the retinal microvasculature from hyperglycemia and other diabetes-associated factors.The severity of DR is closely associated with the development of DFUs and the need for lower extremity revascularization procedures and/or amputation.Like the lower extremity,the eye may also suffer end-organ damage from macrovascular compromise in the form of cranial neuropathies that impair its motility,cause optic neuropathy,or result in partial or complete blindness.Additionally,poor perfusion of the eye can cause ischemic retinopathy leading to the development of proliferative diabetic retinopathy or neovascular glaucoma,both serious,visionthreatening conditions.Finally,diabetic corneal ulcers and DFUs share many aspects of impaired wound healing resulting from neurovascular,sensory,and immunologic compromise.Notably,alterations in serum biomarkers,such as hemoglobin A1c,ceruloplasmin,creatinine,low-density lipoprotein,and highdensity lipoprotein,are associated with both DR and DFUs.Monitoring these parameters can aid in prognosticating long-term outcomes and shed light on shared pathogenic mechanisms that lead to end-organ damage.The frequent cooccurrence of diabetic eye and foot problems mandate that patients affected by either condition undergo reciprocal comprehensive eye and foot evaluations in addition to optimizing diabetes management. | David J Ramsey James T Kwan Arjun Sharma | 2022 | World Journal of Diabetes2022，13，12： | 2 |
| 2 | The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study显示文摘 | Brian Olshansky Lynda E. Rosenfeld Alberta L. Warner Allen J. Solomon Gearoid O’Neill Arjun Sharma Edward Platia Gregory K. Feld Toshio Akiyama Michael A. Brodsky H.Leon Greene | 2004 | Journal of the American College of Cardiology2004，，7： | 1 |
| 3 | Health care policy and regulatory implications on medical device innovations: a cardiac rhythm medical device industry perspective显示文摘 | Arjun Sharma Anthony Blank Parashar Patel Kenneth Stein | 2013 | Journal of Interventional Cardiac Electrophysiology2013，，： | 1 |
| 4 | Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes显示文摘 | Mihai Gheorghiade Ami N. Shah Muthiah Vaduganathan Javed Butler Robert O. Bonow Giuseppe M.C. Rosano Scott Taylor Stuart Kupfer Frank Misselwitz Arjun Sharma Gregg C. Fonarow | 2013 | Heart Failure Clinics2013，，： | 1 |
| 5 | Microstructural, corrosion and nanomechanical behaviour of ceramic coatings developed on magnesium AZ31 alloy by micro arc oxidation显示文摘 | Arjun Dey R.Uma Rani Hari Krishna Thota Anand Kumar Sharma Payel Bandyopadhyay Anoop Kumar Mukhopadhyay | 2012 | Ceramics International2012，，： | 1 |
| 6 | Health care policy and regulatory implications on medical device innovations:a cardiac rhythm medical device industry perspective显示文摘 | Arjun Sharma Anthony Blank Parashar | 2013 | Journal of interventional cardiac electrophysiology:an international journal of arrhythmias and pacing2013，36，2： | 1 |
| 7 | The DAVID (Dual Chamber and VVI Implantable Defibrillator) II Trial显示文摘 | Bruce L. Wilkoff Peter J. Kudenchuk Alfred E. Buxton Arjun Sharma James R. Cook Anil K. Bhandari Michael Biehl Gery Tomassoni Anna Leonen Linette R. Klevan Alfred P. Hallstrom | 2009 | Journal of the American College of Cardiology2009，，10： | 1 |
| 8 | Identification and quantitative estimation of Emodin in Rhei Emodi Wall.Rhizome and the relevant polyherbal ayurvedic formulation显示文摘The present study explored quality control of plant drug and polyherbal formulation using HPTLC and HPLC fingerprinting.The study combined qualitative analysis of Emodin and Rhein biomarker compound in Rhei Emodi Wall.rhizome extract and polyherbal formulation extract by HPTLC method with quantitative estimation of Emodin by HPLC method,aiming to help in accurate identification of Emodin and Rhein in plant materials,polyherbal formulations.This study also checked adulteration,with the purpose of improving bio-efficacy of ayurvedic formulation.All the samples showed characteristic peaks of Emodin at same retention time as that of standard Emodin.According to the HPTLC fingerprinting results,the Rf values of Rhein reference standard at 0.42 and Emodin at 0.62 were observed in test solution of Rhei emodi Wall.rhizome extract and polyherbal formulation extract and both were found comparable.The quantitative evaluation of Emodin present in the polyherbal formulation and Rhei emodi Wall.rhizome extracts were 0.0177% and 0.3106% respectively. | Ajay Kumar Meena R.Ilavarasan Arjun Singh Lavkush Sharma Amit Dixit N.Srikanth | 2021 | Asian Journal of Traditional Medicines2021，16，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员